| 4456 |
Centers for Disease Control and Prevention |
Html |
en |
Interim Additional Guidance for Infection Control for Care of Patients with Confirmed, Probable, or Suspected Novel Influenza A (H1N1) Virus Infection in Outpatient Hemodialysis Settings |
null |
| healthcare personnel | 0.252511 |
| febrile respiratory illness | 0.406786 |
| new patient | 0.287306 |
| Standard Precautions | 0.302468 |
| virus infection control | 0.456196 |
| outpatient dialysis | 0.285598 |
| eye protection | 0.255526 |
| novel influenza | 0.507903 |
| nearest patient stations | 0.429093 |
| patient meeting criteria | 0.426577 |
| staff caring | 0.252019 |
| hemodialysis patients | 0.547575 |
| recommendations supplement | 0.290833 |
| Disease Control | 0.28766 |
| influenza isolation precautions | 0.72742 |
| N95 respirator | 0.275418 |
| sore throat | 0.271952 |
| higher level | 0.263522 |
| novel H1N1 infection | 0.479871 |
| symptomatic patients | 0.31274 |
| general infection control | 0.453302 |
| novel H1N1 influenza | 0.912637 |
| dialysis station | 0.273162 |
| surgical mask | 0.425672 |
|
| H1N1 influenza isolation | 0.685167 |
| isolation room | 0.303626 |
| nasal congestion | 0.271879 |
| standard facility protocols | 0.37562 |
| end-of-row station | 0.266141 |
| nonsterile gloves | 0.250414 |
| Interim Guidance | 0.275447 |
| outpatient hemodialysis | 0.334975 |
| hand sanitizer | 0.261978 |
| virus infection | 0.466409 |
| MMWR report | 0.249511 |
| hepatitis B surface | 0.501324 |
| antigen positive patients | 0.63797 |
| Hepatitis B isolation | 0.33275 |
| infection control recommendations | 0.724766 |
| surface antigen | 0.524168 |
| Healthcare Setting | 0.278225 |
| case definition | 0.26329 |
| Suspected Swine Influenza | 0.565156 |
| Chronic Hemodialysis Patients | 0.456263 |
| influenza virus | 0.353348 |
| PM ET | 0.286161 |
| separate room | 0.412271 |
|
CLICK HERE |
| 6049 |
Centers for Disease Control and Prevention |
Html |
en |
Parathion - NIOSH Pocket Guide to Chemical Hazards |
null |
| MPEG | 0.378858 |
| search | 0.263099 |
| PDF | 0.261307 |
| PPT | 0.446092 |
|
| DOC | 0.368812 |
| information | 0.262482 |
| different file formats | 0.938484 |
| page | 0.276773 |
|
CLICK HERE |
| 6442 |
Centers for Disease Control and Prevention |
Html |
en |
Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| John A. Jereb | 0.564183 |
| new combination regimen | 0.56385 |
| susceptible M. tuberculosis | 0.523827 |
| radiographic findings | 0.545792 |
| new regimen | 0.553701 |
| clinical trials | 0.6653 |
| TB epidemiology | 0.590454 |
| U.S. standard regimen | 0.572275 |
| Mycobacterium tuberculosis infection | 0.527238 |
| TB Prevention | 0.570053 |
| tuberculin skin | 0.597718 |
| expert opinion | 0.549948 |
| patients | 0.638723 |
| treatment trials | 0.617764 |
| randomized clinical trial | 0.66679 |
| M. tuberculosis | 0.714292 |
| contagious TB | 0.651968 |
| extrapulmonary TB | 0.577697 |
| high quality evidence | 0.584239 |
| possible INH-RPT hypersensitivity | 0.540519 |
| adverse effects | 0.843422 |
| INH-RPT clinical trials | 0.641618 |
| randomized clinical trials | 0.607413 |
| TB risk factors | 0.624867 |
| treatment adverse effects | 0.548831 |
|
| TB preventive therapy | 0.642536 |
| treatment | 0.633906 |
| daily INH | 0.648966 |
| 9-month INH regimen | 0.608614 |
| quality evidence | 0.59853 |
| TB elimination | 0.613701 |
| TB disease | 0.600232 |
| INH monotherapy | 0.526911 |
| antiretroviral treatment | 0.522933 |
| INH-RPT regimen | 0.630851 |
| daily INH regimens | 0.609746 |
| INH-RPT recipients | 0.534752 |
| Severe adverse effects | 0.547647 |
| lower quality evidence | 0.575252 |
| patient categories | 0.551552 |
| active TB | 0.623606 |
| TB cases | 0.588042 |
| LTBI | 0.571977 |
| tuberculin skin test | 0.577336 |
| TB | 0.91141 |
| self-supervised daily INH | 0.619797 |
| permanent drug discontinuations | 0.563695 |
| daily self-supervised INH | 0.611881 |
| pulmonary TB | 0.683866 |
|
CLICK HERE |
| 6537 |
Centers for Disease Control and Prevention |
Html |
en |
CDC Ramps up Support for Final Push in Global Polio Eradication Effort - Polio Eradication - CDC Works For You 24/7 |
CDC Works For You 24/7 Protecting People - CDC Ramps up Support for Final Push in Global Polio Eradication Effort - On Wednesday, December 14, 2011, CDC Director Thomas R. Frieden, M.D., M.P.H., charged the entire CDC community to become active participants in an intensified strategy to eradicate polio, worldwide. The briefing followed Dr. Frieden’s December 2nd announcement activating CDC’s Emergency Operations Center for the agency’s partnership engagement through the Global Polio Eradication Initiative (GPEI). |
| U. S. | 0.375215 |
| partnership engagement | 0.378994 |
| polio vaccine administration | 0.700783 |
| PSU staff | 0.395645 |
| CDC’s Emergency | 0.609676 |
| 20th century | 0.371621 |
| CDC Director Thomas | 0.621534 |
| Disease Control | 0.370134 |
| early 1960s | 0.371322 |
| EIS officers | 0.408069 |
| latest chapter | 0.370267 |
| national polio surveillance | 0.679188 |
| Global Polio Eradication | 0.769568 |
| entire CDC community | 0.619133 |
| Epidemic Intelligence Service | 0.52829 |
| surveillance data | 0.376211 |
| global push | 0.372205 |
| CDC’s role | 0.504852 |
| Emergency Operations Center | 0.585285 |
| feared diseases | 0.37921 |
| active participants | 0.381138 |
| Chief Epidemic Intelligence | 0.432706 |
| global public health | 0.433912 |
| massive vaccination effort | 0.433869 |
| western hemisphere | 0.373081 |
|
| infectious viral disease | 0.440096 |
| founder Alex Langmuir | 0.430687 |
| intensified strategy | 0.3919 |
| U.S. Centers | 0.370185 |
| Polio-Free U.S. | 0.375538 |
| Vaccine Efforts | 0.406443 |
| CDC’s PSU | 0.532221 |
| memory forever. | 0.368713 |
| Chief EIS Officer | 0.463767 |
| public health | 0.439496 |
| Dr. Jonas Salk | 0.476725 |
| CDC’s mission | 0.510592 |
| significant public health | 0.431007 |
| entire world | 0.37016 |
| R. Frieden | 0.406798 |
| CDC’s polio | 0.75788 |
| polio | 0.925923 |
| Sabin polio vaccines | 0.722491 |
| Ira L. Myers | 0.427867 |
| oral polio vaccine | 0.695775 |
| CDC’s Epidemic | 0.514671 |
| late 1940s | 0.375947 |
| Dr. Albert Sabin | 0.468511 |
| Dr. Frieden | 0.408036 |
|
CLICK HERE |
| 9204 |
Centers for Disease Control and Prevention |
Html |
en |
Preventing Chronic Disease | Raising Awareness of Sleep as a Healthy Behavior - CDC |
Sleep is an essential component of health, and its timing, duration, and quality are critical determinants of health. Sleep may play an important role in metabolic regulation, emotion regulation, performance, memory consolidation, brain recuperation processes, and learning. |
| multisectoral public health | 0.403492 |
| sleep health | 0.648612 |
| public health practitioners | 0.420436 |
| average basal sleep | 0.62096 |
| sleep behavior | 0.609079 |
| primary care providers | 0.409285 |
| substantial public health | 0.412596 |
| Disease Control | 0.398568 |
| public health approaches | 0.409736 |
| public health risk | 0.414903 |
| health care providers | 0.493464 |
| critical public health | 0.403564 |
| sleep initiation | 0.5637 |
| numerous health conditions | 0.396517 |
| optimal sleep duration | 0.63055 |
| public health partners | 0.406262 |
| poor sleep quality | 0.61421 |
| sleep maintenance | 0.564598 |
| insufficient sleep | 0.93247 |
| public health investigations | 0.408645 |
| Lead Health Scientist | 0.385708 |
| sleep deprivation | 0.678459 |
| appropriate sleep time | 0.590834 |
| care health providers | 0.397461 |
| sleep research | 0.599101 |
|
| drowsy driving | 0.383564 |
| public health issue | 0.422258 |
| important public health | 0.460875 |
| health care screening | 0.401447 |
| major health consequences | 0.396821 |
| sleep loss | 0.593027 |
| sufficient sleep | 0.554248 |
| health risk factors | 0.392304 |
| public health burden | 0.453411 |
| sleep apnea symptoms | 0.575926 |
| public health professionals | 0.448509 |
| public health | 0.751803 |
| short sleep duration | 0.680628 |
| sleep disorders | 0.671566 |
| healthy sleep habits | 0.599749 |
| National Sleep Awareness | 0.613483 |
| physical activity | 0.42976 |
| healthy sleep | 0.61204 |
| motor vehicle accidents | 0.439084 |
| Public Health Service | 0.405267 |
| sleep screening | 0.579047 |
| sleep counseling | 0.569982 |
| primary care | 0.43185 |
| Sleep Awareness Roundtable | 0.588455 |
|
CLICK HERE |
| 10240 |
Centers for Disease Control and Prevention |
Html |
en |
Frostbite'Winter Weather |
Taking preventive action is your best defense against having to deal with extreme cold-weather conditions. By preparing your home and car in advance for winter emergencies, and by observing safety precautions during times of extremely cold weather, you can reduce the risk of weather-related health problems. |
| temperatures | 0.458116 |
| winter storms | 0.788413 |
| stages | 0.371516 |
|
| challenge | 0.397336 |
| winter storm | 0.722421 |
|
CLICK HERE |
| 10398 |
Centers for Disease Control and Prevention |
Html |
en |
Heart-Healthy and Stroke-Free: A Social Environment Handbook|Publications|DHDSP |
null |
| health promotion activities | 0.518452 |
| stroke health promotion | 0.428141 |
| social environmental interventions | 0.39043 |
| high blood cholesterol | 0.417445 |
| adverse risk conditions | 0.381903 |
| family incomes | 0.423762 |
| social environment | 0.675908 |
| behavioral risk factors | 0.405327 |
| cardiovascular health promotion | 0.38572 |
| risk factors | 0.910055 |
| individual risk factors | 0.426793 |
| social environmental conditions | 0.401675 |
| blood cholesterol level | 0.420349 |
| high-risk population | 0.44933 |
| public health tools | 0.410347 |
| stroke risk factors | 0.54102 |
| blood cholesterol | 0.841857 |
| social environment paradigm | 0.481206 |
| individual goal | 0.428957 |
| low-risk population | 0.37951 |
| social environmental change | 0.460059 |
| normal blood pressure | 0.451663 |
| blood cholesterol levels | 0.529914 |
| specific risk factors | 0.392453 |
| social environmental promoters | 0.403054 |
|
| health promotion | 0.920043 |
| well-known risk factors | 0.39612 |
| normal blood cholesterol | 0.429486 |
| population goal | 0.457734 |
| health education paradigm | 0.397526 |
| heart disease | 0.875098 |
| social environmental barriers | 0.408088 |
| health promotion activity | 0.478579 |
| public health professionals | 0.422517 |
| corresponding population goal | 0.405251 |
| public health | 0.498548 |
| health promotion community | 0.393766 |
| individual patient education | 0.399966 |
| fundamental social change | 0.409181 |
| public health programs | 0.429087 |
| individual goals | 0.371773 |
| Health promotion efforts | 0.40986 |
| local public health | 0.411877 |
| high blood pressure | 0.448509 |
| population goals | 0.514269 |
| individual lifestyle choices | 0.38363 |
| conceptual model | 0.475213 |
| high-risk population goal | 0.4185 |
| elevated blood cholesterol | 0.419128 |
|
CLICK HERE |
| 12182 |
Centers for Disease Control and Prevention |
Html |
en |
Clinical Inquiries Regarding Ebola Virus Disease Received byCDC - United States, July 9-November 15, 2014 |
Please note: An erratum has been published for this article. To view the erratum, please click here. |
| CDC | 0.550432 |
| Ebola virus testing | 0.509368 |
| United States | 0.607627 |
| epidemiologic risk factor | 0.202675 |
| CDC Laboratory Response | 0.261412 |
| Ebola risk factors | 0.380866 |
| Ebola virus test | 0.359409 |
| Ebola virus | 0.903851 |
| Ebola outbreak response | 0.415401 |
| Ebola virus tests | 0.34261 |
| alternative diagnoses | 0.219569 |
| state health departments | 0.238185 |
| Zoonotic Infectious Diseases | 0.208851 |
| health departments | 0.49983 |
| health care workers | 0.237819 |
| health care providers | 0.795102 |
| local health departments | 0.310569 |
| public health | 0.508869 |
| Ebola Response Team | 0.394035 |
| laboratory-confirmed Ebola | 0.39293 |
|
| National Center | 0.249464 |
| Ebola-affected country | 0.217199 |
| CDC staff | 0.203978 |
| epidemiologic risk factors | 0.206314 |
| public health officials | 0.261241 |
| Emergency Operations Center | 0.214532 |
| local public health | 0.416212 |
| potential Ebola cases | 0.343755 |
| persons | 0.269153 |
| Ebola patient | 0.459769 |
| possible Ebola exposure | 0.34484 |
| epidemiologic risk | 0.213819 |
| Ebola patients | 0.38148 |
| public health laboratories | 0.225315 |
| clinical inquiries | 0.312142 |
| Ebola test results | 0.37348 |
| Ebola | 0.906062 |
| public health laboratory | 0.207787 |
| active monitoring | 0.201281 |
|
CLICK HERE |
| 13153 |
Centers for Disease Control and Prevention |
Html |
en |
Announcement: National Campaign to Prevent Falls inConstruction - United States, 2015 |
In 2013 and 2014, construction employment began to recover from the 2007–2009 economic downturn. In 2014, construction employment grew to 9.8 million workers from 8. |
| media construction | 0.773668 |
| labor organizations | 0.746199 |
| construction-related employers | 0.741827 |
| fatal work-related injuries | 0.913441 |
| public health practitioners | 0.859009 |
| Human Services | 0.833009 |
| Prevent Falls | 0.747927 |
| onsite supervisors | 0.74116 |
| MMWR HTML versions | 0.844922 |
| U.S. Department | 0.829792 |
| state agencies | 0.735371 |
| electronic PDF version | 0.833253 |
| federal government agencies | 0.863025 |
| national campaign | 0.750642 |
| additional information | 0.740245 |
| National Safety Stand-Down | 0.870421 |
| trade associations | 0.742657 |
| Contact GPO | 0.756795 |
| construction sites | 0.79059 |
| fall prevention requirements | 0.850536 |
| industry sector | 0.764849 |
| private industry | 0.746278 |
| original paper copy | 0.839267 |
| construction contractors | 0.772225 |
|
| federal Occupational Safety | 0.859927 |
| United States | 0.735417 |
| U.S. Government Printing | 0.845486 |
| original MMWR paper | 0.840369 |
| prevention campaign | 0.737729 |
| local stand-downs | 0.736502 |
| daily basis | 0.738772 |
| MMWR readers | 0.740224 |
| construction sector stakeholders | 0.920137 |
| construction occupations | 0.788066 |
| economic downturn | 0.774697 |
| highest number | 0.7522 |
| professional organizations | 0.746389 |
| 50 states | 0.736336 |
| fatal work injuries | 0.907322 |
| Health Administration | 0.758929 |
| private construction sector | 0.934498 |
| construction employment | 0.888886 |
| typeset documents | 0.734562 |
| trade names | 0.73429 |
| preventable public health | 0.889849 |
| Broad engagement | 0.734821 |
| non-CDC sites | 0.736258 |
| government-labor-management partnership | 0.735991 |
|
CLICK HERE |
| 14171 |
Centers for Disease Control and Prevention |
Html |
en |
Notes from the Field: Administration Error Involving aMeningococcal Conjugate Vaccine - United States, March 1,2010-September 22, 2015 | MMWR |
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC). |
| Figure). | 0.561058 |
| proper administration | 0.538403 |
| unspecified diluent | 0.518879 |
| Menveo | 0.762847 |
| Haemophilus influenzae type | 0.60897 |
| Similar errors | 0.548203 |
| CDC | 0.534779 |
| invasive meningococcal disease | 0.644655 |
| administration | 0.696196 |
| original MMWR paper | 0.596877 |
| vaccine labeling | 0.650287 |
| Human Services | 0.584567 |
| certain immunosuppressive conditions | 0.640999 |
| Drug Administration | 0.628687 |
| U.S. Department | 0.584684 |
| administration errors | 0.577445 |
| MenCYW-135 liquid component | 0.690413 |
| vaccine administration | 0.672757 |
| John R. Su | 0.592537 |
| Healthcare Quality Promotion | 0.591107 |
| intramuscular injection | 0.521258 |
| meningococcal conjugate vaccine | 0.760626 |
| electronic PDF version | 0.592896 |
| Novartis AG | 0.525277 |
|
| following Menveo immunization | 0.653073 |
| Zoonotic Infectious Diseases | 0.589519 |
| liquid MenCYW-135 component | 0.824702 |
| vaccine preparation | 0.669037 |
| format errors | 0.546036 |
| similarly packaged vaccines | 0.611503 |
| VAERS | 0.58697 |
| immunization provider | 0.521962 |
| MenA component | 0.649964 |
| inactivated poliovirus vaccine | 0.736607 |
| different liquid vaccine | 0.77484 |
| vaccine component | 0.68212 |
| conjugate vaccine | 0.791891 |
| Vaccine Adverse Event | 0.786571 |
| improperly prepared dose | 0.621676 |
| vaccine | 0.949338 |
| properly prepared dose | 0.635286 |
| recipients | 0.595434 |
| resulting solution | 0.518289 |
| reported adverse events | 0.641414 |
| repeat dose | 0.607661 |
| empiric Bayesian methods | 0.617509 |
| errors | 0.598749 |
|
CLICK HERE |